A recent study suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop conventional lifestyle regimens.
Published data in a major health publication demonstrates that while obese individuals frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals using such medications must be cognizant of the potential of rapid weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight within about a year and a half.
Analyzing Approaches
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the effects of these new drugs with other pills.
Scientists note that individuals who lose weight through diet and exercise usually have a slower weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Rebound
Nutrition scientists propose the mechanism of the injections explains the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which controls hunger.
"Artificially providing the hormone levels several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means hunger is uncontrolled, making excessive eating far more likely."
An Ongoing Disease?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians contend that, due to the high risk of relapse, the treatment should be considered ongoing.
This opinion is echoed by pharmaceutical companies, who note that the findings "underscore the chronic character of excess weight," comparing it to managing conditions like high blood pressure.
Patient Experiences
Users who have come off the medication report a sudden return of appetite.
"It felt as if a switch activating and you become ravenous," said one woman.
The struggle is compounded if individuals have not developed lasting lifestyle or habit modifications during therapy.
Growing Adoption
Figures show that millions of people in the UK have used these injections in the past year, with demand continuing to grow.
- Use is higher among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and maintained weight loss relies on integrated behavioural support.
